[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Medroxyprogesterone Acetate (Depo-Provera)". It is a popular hormonal contraceptive or birth control product which is injected every 3 months. Depo-Provera contains pregnane (17α-hydroxyprogesterone derivative) progestin, medroxyprogesterone acetate, without estrogen, and is administered to women in the form of an intramuscular injection once every 11 to 13 weeks.

YEAR:

1990

CATEGORY:

Medroxyprogesterone Acetate (Depo-Provera)

TITLE

Medroxyprogesterone (Depo Provera) and breast cancer [letter]

AUTHORS

McCowan L

SOURCE

NEW ZEALAND MEDICAL JOURNAL. 1990 May 9;103(889):225-6.

ABSTRACT

The recent Clinical Services newsletter drew attention to the paper by Paul and Skegg, which suggested a doubling

in the risk of breast cancer for women under 35 who had used Depo Provera. The greatest relative risk (4.6) was

associated with use for 2 or more years before the age of 25, but numbers of cases and controls in these groups

were small (5 and 11 respectively). Results of larger studies will be available shortly. In the meantime, women

considering using Depo Provera need to be made aware of this preliminary data and the risks put into perspective.

The risk of getting breast cancer under 35 is about 1 in 500 and this may increase to 2 in 500 women who have used

Depo Provera. There was no increased risk for women over 35 who used Depo Provera. Depo Provera is not a

contraceptive of 1st choice for the majority of New Zealand women, however, it needs to be preserved as an option for

women with specific contraceptive and medical problems and for those for whom it is their favored contraceptive

method. With Depo Provera, as with any other contraceptive method, women need to be fully counselled regarding

risks and benefits. Contraceptive Choice has recently modified its Depo Provera pamphlet to include reference to the

Paul Study. These are available from: Contraceptive Choice, PO Box 60-157, Titirangi. (PubHealth.info Document

ID: MEDRT 331-06)

PubHealth.info NOTE: The author(s) of this article titled, "Medroxyprogesterone (Depo Provera) and breast cancer

[letter]", is(are) McCowan L. The source of this article is "NEW ZEALAND MEDICAL JOURNAL. 1990 May

9;103(889):225-6.". This article was published in 1990 in English language(s). (PubHealth.info® Document ID:

MEDRT 331-06. All rights reserved with PubHealth.info) PIN: 331

© Copyrights PubHealth.info®, an information portal on public health. All rights reserved.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.